Syngene Launches Platform for Rapid, Enhanced Potein Production

Overview

Syngene International, the global contract research, development and manufacturing organization (CRDMO) has unveiled its new protein production platform. This accelerates enhanced protein production, enabling quicker preclinical and clinical development as well as product launches, thereby reducing time to market.

ExcellGene With Coupled with Syngene’s and Development Processes

The new platform is using a cell line and transposon-based technology in-licensed from Swiss biotech services company, ExcellGene, coupled with Syngene’s clone selection and development processes, promises significant improvement in efficiency and precision. 

Words from Syngene International

• "By combining the cell line and transposon-based platform from ExcellGene with our proprietary processes, we are pushing the boundaries in cell line development. This innovative approach will not only accelerate development timelines but also enhance the overall reliability and efficiency of the process, delivering substantial benefits to our clients,"" said Sridevi Khambhampaty, vice president, biopharmaceutical development, Syngene International.
• According to Alex Del Priore, senior vice president, manufacturing services, Syngene International, “We see biologics as a key driver of future growth and we are committed to investing in advanced technology to achieve reliability, precision and speed for clients.  By combining Syngene’s skills and experience with ExcellGene’s best-in-class cell line development technology, we can expedite getting molecules to market for the people and patients who need them.” 

From ExcellGene

• “High yield manufacturing is a multifactorial exercise that starts with transfections and an optimised cell host. We are obviously delighted to partner with and to contribute to Syngene’s process development and manufacturing capabilities. This will leverage our technology and our cells which is CHOExpress for the benefit of their extensive client base.” 
• “Having studied the profound challenges in DNA transfer to cultivated cells for decades and linked insights from such studies to their phenotypes and use in manufacturing our  work, combined with the talent and expertise of the Syngene team, will directly benefit patients around the world,” said Maria J. and Florian M Wurm, co-founders and managers, ExcellGene

About this New Platform

• The new platform streamlines clone selection and enhances operational productivity. It also supports a wide range of biomolecules including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates and other recombinant proteins. 
• This versatility facilitates integration with both perfusion and fed-batch manufacturing processes. 
• A track record in developing multiple monoclonal antibodies with the new technology underscores its effectiveness and reinforces Syngene’s ability to provide innovative solutions for its clients, stated the communication from the companies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!